Determining the safety and feasibility of unilateral cell therapy delivery to the substantia nigra for the goal of disease modification. (October 2020) - Slevin, J.; Quintero, J.; Gurwell, J.; Guduru, Z.; Yamasaki, T.; Koehl, L.; Hines, T.; El Seblani, N.; Gerhardt, G.; van Horne, C.